NEWS
News Articles
As Georgia Tech’s Science Square nears completion, it seeks more tenants
From university spinoffs to publicly traded life science companies, activity is swirling around Georgia Tech’s $1 billion development Science Square. But with the 18-acre project’s completion set for March leasing has been slow. Venture capital company Portal Innovations is building out 33,000 square feet of lab and office space. Otherwise, no leases have been signed.…
Read MoreSIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors
HUMMELSTOWN, Pa., Dec. 12, 2023 (GLOBE NEWSWIRE) — SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for the Company’s lead product candidate, SIRPant-M™,…
Read MoreAdvaMed Announces Formation of Medical Imaging Division
World’s largest medical imaging companies join world’s largest medtech association WASHINGTON, D.C., – Today, AdvaMed, the Medtech Association, announced the establishment of a new Medical Imaging Technology division focused on advocating on behalf of large and small companies for the essential role of medical imaging technology, radiopharmaceuticals, contrast media, and focused ultrasound devices in our nation’s health care…
Read MorePeter J. Arduini, President and CEO of GE HealthCare, Named Chair of AdvaMed Board of Directors
December 11, 2023 | WASHINGTON, D.C., – Today, AdvaMed, the Medtech Association, announced that Peter J. Arduini, president and CEO of GE HealthCare, will become the Chair of the AdvaMed Board of Directors. “The entire board and the global industry AdvaMed represents are very excited to have Peter as our new Board Chair during this critical…
Read MoreUsing March-In as a Price Control Mechanism Is a “Dangerous Precedent To Set”
The White House just announced plans to use Bayh-Dole “march-in rights” to step in and license patent rights of drugs “developed with federal funding” to other manufacturers when the price of the drug is deemed too high. BIO’s Chief Advocacy Officer, Nick Shipley, made the following statement: “Using the Bayh-Dole Act’s march-in process as a mechanism…
Read MoreIndustry Leader and Globally Recognized Patient Advocate John F. Crowley Appointed to Lead BIO as President & CEO
Biotech entrepreneur, company founder, tireless patient advocate, and U.S. Navy combat veteran will guide the life science industry in its mission to feed, fuel and heal the world December 5, 2023 | The Biotechnology Innovation Organization (BIO) is proud to announce that industry leader and military veteran John F. Crowley will be its new President…
Read More